The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sangamo Therapeutics Inc (Sangamo) is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFP candidates are based on its proprietary gene therapy technologies. The ZFPs-based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and the production of transgenic animals. Sangamo's major products include gene therapies and genomic medicines targeting neurological disorders, autoimmune diseases, and oncology. The company also collaborates with other pharmaceutical companies to develop and commercialize its therapies. Sangamo is headquartered in Brisbane, California, the US.Sangamo Therapeutics Inc Key Recent Developments
- May 11, 2026: Sangamo Therapeutics Schedules First Quarter 2026 Earnings Call
- Mar 30, 2026: Sangamo Therapeutics Reports Business Highlights and Q4 and Full-Year 2025 Financial Results
- Dec 18, 2025: Sangamo Therapeutics Begins Rolling BLA Submission to U.S. FDA for ST-920 in Fabry Disease
- Dec 02, 2025: Sangamo Therapeutics Receives FDA Fast Track Designation for ST-503 in Small Fiber Neuropathy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vertex Pharmaceuticals Inc
- Sonoma Biotherapeutics Inc
- Quell Therapeutics Ltd
- GentiBio Inc
- CRISPR Therapeutics AG
- Beam Therapeutics Inc
- Allogene Therapeutics Inc
- Sigilon Therapeutics Inc
- Precision Biosciences Inc
- Cellectis SA
- Protalix BioTherapeutics Inc
- Genentech Inc
- Editas Medicine Inc
- Amgen Inc
- Taysha Gene Therapies Inc
- GSK plc
- 4D Molecular Therapeutics Inc
- Lyell Immunopharma Inc
- Genzyme Corp
- Spark Therapeutics Inc
- Acceleron Pharma Inc
- Abata Therapeutics
- Cellenkos Inc
- BioMarin Pharmaceutical Inc

